Ignite Creation Date:
2024-05-06 @ 3:14 PM
Last Modification Date:
2024-10-26 @ 1:45 PM
Study NCT ID:
NCT04566952
Status:
UNKNOWN
Last Update Posted:
2020-10-30
First Post:
2020-09-24
Brief Title:
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
Sponsor:
Xiaoxiang Chen
Organization:
Jiangsu Cancer Institute Hospital
Organization Data
Organization:
Jiangsu Cancer Institute Hospital
Class:
OTHER
Study ID:
JiangsuCH002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Xiaoxiang Chen
Lead Sponsor Class:
OTHER
Responsible Party:
Xiaoxiang Chen
Responsible Party Title:
Academic secretary of gynecological oncology Committee of Jiangsu anti cancer association
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Jiangsu Cancer Institute Hospital
Old Name:
None
Old Organization:
None